Natera shared a post on X:
“It has been a big week for Natera.
On Monday, new clinical practice guidelines were issued in bladder cancer, marking another important ‘first’ for MRD-guided care and a major milestone for patients. This landmark update includes a recommendation for ctDNA-MRD testing using our Signatera technology in muscle-invasive bladder cancer (MIBC).
On Tuesday, Signatera received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for patients with colorectal cancer (CRC). With this approval, Signatera is the first MRD test approved by PMDA in Japan.
Coming on the heels of our recent FDA approval of Signatera CDx in MIBC in May, these milestones highlight the strength of our science, the value of our global partnerships, and the momentum we are building worldwide. We celebrate them together with our patients, clinicians, and the teams who made them possible.
These are significant steps forward, and just the beginning!”
Proceed to the video attached to the post.
More posts about Natera.